Jer-Yuarn Wu

The paper evaluates the clinical impact of pharmacogenetic risk variants in a large Han Chinese cohort, finding that while most carry risk variants, the excess risk of adverse events is small and most patients do not experience adverse outcomes.

The paper analyzes 292 disease-relevant deleterious variants in 486,956 participants to assess their risk differences, finding most have minimal impact.